Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [82]
Citations
Cites
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,186
Self-citationAversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Self-citationRole of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Self-citationHematopoietic Cell Transplantation
Forman, S. J., & Nakamura, R. (2015) · Blackwell Science Ltd eBooks · Cited by 659
Aversa, F., Tabilio, A., Terenzi, A., Velardi, A., Falzetti, F., Giannoni, C., Iacucci, R., Zei, T., Martelli, M., & Gambelunghe, C. (1994) · Blood · doi:10.1182/blood.v84.11.3948.bloodjournal84113948 · Cited by 576
Self-citationColonna, M., Borsellino, G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.12000 · Cited by 460
Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
Bachar-Lustig, E., Rachamim, N., Li, H.-W., Lan, F., & Reisner, Y. (1995) · Nature Medicine · doi:10.1038/nm1295-1268 · Cited by 322
Generation of Allospecific Natural Killer Cells by Stimulation Across a Polymorphism of HLA-C
Colonna, M., Brooks, E. G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Science · doi:10.1126/science.8493555 · Cited by 234
Research works printed but not linked: 3
- Valiante N. M., Parham P., Biol. Blood Marrow Transplant. 3, 229 (1997).
- A supplementary table and experimental procedures are available on Science Online at www.sciencemag.org/cgi/content/full/295/5562/2097/DC1.
- We thank A. Santucci for statistical analyses L. Romani for critical review of the manuscript and G. Boyd for her essential role in manuscript editing. Supported by grants from the Italian Association for Cancer Research the Italian Ministry of Research and the Italian Ministry of Health and by a translational research grant from the Leukemia and Lymphoma Society. W.D.S. is supported by NIH grant number HL03979.
Cited by
Items 101–200 of 1,002
CD56 in the Immune System: More Than a Marker for Cytotoxicity?
Van Acker, H. H., Capsomidis, A., Smits, E. L., & Van Tendeloo, V. F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00892 · Cited by 388
Fauriat, C., Just-Landi, S., Mallet, F., Arnoulet, C., Sainty, D., Olive, D., & Costello, R. T. (2007) · Blood · doi:10.1182/blood-2005-08-027979 · Cited by 380
“Seven of 71 (10%) patients had favorable karyotype abnormalities—3 with inv(16), 2 with t(8;21), and 2 with t(15;17).”
BackgroundChimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01083-5 · Cited by 379
“An interesting property of mature NK cells for adoptive cell therapy is that they can be transplanted into a new surrounding with different MHC expression patterns without losing their function [23, 24].”
BackgroundImmune modulation by mesenchymal stem cells
Rasmusson, I. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.03.019 · Cited by 374
Pende, D., Marcenaro, S., Falco, M., Martini, S., Bernardo, M. E., Montagna, D., Romeo, E., Cognet, C., Martinetti, M., Maccario, R., et al. (2009) · Blood · doi:10.1182/blood-2008-06-164103 · Cited by 378
“This kind of receptor repertoire can lead to alloreactivity in haplo-HSCT through the mechanism of “missing self” recognition,18 provided that the donor (1) expresses a KIR-ligand that is missing in the recipient’s HLA genotype and (2) expresses the specific KIR, leading to a KIR/KIR-ligand mismatch in graft-versushos…”
BackgroundGleason, M. K., Lenvik, T. R., McCullar, V., Felices, M., O'Brien, M. S., Cooley, S. A., Verneris, M. R., Cichocki, F., Holman, C. J., Panoskaltsis-Mortari, A., et al. (2012) · Blood · doi:10.1182/blood-2011-06-360321 · Cited by 373
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants
Davies, S. M., Ruggieri, L., DeFor, T., Wagner, J. E., Weisdorf, D. J., Miller, J. S., Velardi, A., & Blazar, B. R. (2002) · Blood · doi:10.1182/blood-2002-04-1197 · Cited by 368
“An AML-specific effect might be observed in unrelated donor transplantations only if strategies from haploidentical transplantations are used: (1) transplantation of high doses of stem cells, (2) extensive T-cell depletion, (3) no postgrafting immunosuppression, and (4) donors selected for the “perfect mismatch” at HL…”
MethodSelf-citationPende, D., Spaggiari, G. M., Marcenaro, S., Martini, S., Rivera, P., Capobianco, A., Falco, M., Lanino, E., Pierri, I., Zambello, R., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3548 · Cited by 374
Pathophysiology of Graft-Versus-Host Disease
Ferrara, J. L. M., & Reddy, P. (2006) · Seminars in Hematology · doi:10.1053/j.seminhematol.2005.09.001 · Cited by 363
Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M., Umansky, V., Paschen, A., Sucker, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36022 · Cited by 347
Self-citationCiurea, S. O., Schafer, J. R., Bassett, R., Denman, C. J., Cao, K., Willis, D., Rondon, G., Chen, J., Soebbing, D., Kaur, I., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785659 · Cited by 345
Luznik, L., O'Donnell, P. V., & Fuchs, E. J. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.09.005 · Cited by 336
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Kamiya, T., Seow, S. V., Wong, D., Robinson, M., & Campana, D. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123955 · Cited by 342
“In patients with acute myeloid leukemia (AML), responses associated with NK cells have been reported after allogeneic hematopoietic stem cell transplantation (3–5) and after infusion of NK cells activated ex vivo by cytokines (4, 6).”
Chang, Y.-H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3558 · Cited by 329
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
Xiao, L., Cen, D., Gan, H., Sun, Y., Huang, N., Xiong, H., Jin, Q., Su, L., Liu, X., Wang, K., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.011 · Cited by 323
“Importantly, transplantation from NK cell alloreactive donors has produced beneficial graft-versus-leukemia outcome and protected patients against graft rejection and detrimental graftversus-host disease (GVHD).(2) The favorable therapeutic and safety profile of allogeneic NK cell therapy is considered as an important…”
BackgroundBorg, C., Jalil, A., Laderach, D., Maruyama, K., Wakasugi, H., Charrier, S., Ryffel, B., Cambi, A., Figdor, C., Vainchenker, W., et al. (2004) · Blood · doi:10.1182/blood-2004-01-0380 · Cited by 326
Dehn, J., Spellman, S., Hurley, C. K., Shaw, B. E., Barker, J. N., Burns, L. J., Confer, D. L., Eapen, M., Fernandez-Vina, M., Hartzman, R., et al. (2019) · Blood · doi:10.1182/blood.2019001212 · Cited by 323
Campbell, K. S., & Purdy, A. K. (2011) · Immunology · doi:10.1111/j.1365-2567.2010.03398.x · Cited by 329
Interleukin-2, Interleukin-15, and Their Roles in Human Natural Killer Cells
Becknell, B., & Caligiuri, M. A. (2005) · Advances in Immunology · doi:10.1016/s0065-2776(04)86006-1 · Cited by 325
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
Mapara, M. Y., & Sykes, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.041 · Cited by 325
“Furthermore, it has been recently suggested that alloreactive NK cells might be critically involved in mediating graft-versus-leukemia (GVL) effects in the setting of MHC haploidentical hematopoietic stem-cell transplantation [15].”
BackgroundNatural killer cells in human health and disease
Orange, J. S., & Ballas, Z. K. (2006) · Clinical Immunology · doi:10.1016/j.clim.2005.10.011 · Cited by 318
Locatelli, F., Merli, P., Pagliara, D., Li Pira, G., Falco, M., Pende, D., Rondelli, R., Lucarelli, B., Brescia, L. P., Masetti, R., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779769 · Cited by 316
“CD3(1) T cells/mL 231 (1-1618) 254 (23-1472) 668 (153-2596) 1379 (407-3449) CD4(1) T cells/mL 19 (0-442) 89 (4-397) 264 (87-1055) 599 (174-1421) CD8(1) T cells/mL 24 (0-910) 96 (9-1108) 301 (25-1581) 574 (112-2301) ab T cells/mL 47 (1-672) 186 (12-1340) 573 (135-2146) 1291 (259-2795) gd T cells/mL 181 (1-1335) 49 (4-3…”
Yawata, M., Yawata, N., Draghi, M., Partheniou, F., Little, A.-M., & Parham, P. (2008) · Blood · doi:10.1182/blood-2008-03-143727 · Cited by 317
How I treat relapsed childhood acute lymphoblastic leukemia
Locatelli, F., Schrappe, M., Bernardo, M. E., & Rutella, S. (2012) · Blood · doi:10.1182/blood-2012-02-265884 · Cited by 314
“fundamental studies on haplo-HSCT have shown that, in adult patients with AML transplanted in CR, a GvL effect could be mediated by Natural Killer (NK) cells when an HLA-disparate, NK alloreactive relative was employed as donor.(64) This NK-mediated GvL effect has also been documented in children with ALL.”
MethodBreast Cancer Lung Metastasis Requires Expression of Chemokine Receptor CCR4 and Regulatory T Cells
Olkhanud, P. B., Baatar, D., Bodogai, M., Hakim, F., Gress, R., Anderson, R. L., Deng, J., Xu, M., Briest, S., & Biragyn, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4619 · Cited by 312
“The restoration of NK activity is often a sign of better cumulative survival outcome in cancer patients (46, 47).”
Green, M. L., Leisenring, W. M., Xie, H., Walter, R. B., Mielcarek, M., Sandmaier, B. M., Riddell, S. R., & Boeckh, M. (2013) · Blood · doi:10.1182/blood-2013-02-487074 · Cited by 313
Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21102 · Cited by 302
“The renaissance of interest in NK cells in tumor immunosurveillance can be attributed to the discovery of stressinduced ligands for receptors that activate NK cells (23–25) and to the relevance of interactions between MHC class I molecules and killer inhibitory receptors in mismatched hematopoietic transplants, which…”
BackgroundZamai, L., Ponti, C., Mirandola, P., Gobbi, G., Papa, S., Galeotti, L., Cocco, L., & Vitale, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4011 · Cited by 292
“Indeed, strategies that use NK cell donors mismatched for inhibitory NK receptors and MHC-I ligands, present in some allogeneic settings, have been more successful (67, 68).”
BackgroundJenq, R. R., & van den Brink, M. R. M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2804 · Cited by 299
Natural killer cell-mediated immunosurveillance of human cancer
Malmberg, K.-J., Carlsten, M., Björklund, A., Sohlberg, E., Bryceson, Y. T., & Ljunggren, H.-G. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.002 · Cited by 299
Effector and regulatory events during natural killer–dendritic cell interactions
Moretta, L., Ferlazzo, G., Bottino, C., Vitale, M., Pende, D., Mingari, M. C., & Moretta, A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00450.x · Cited by 304
“Experiments in mouse models provided evidence that this reduction is due to the ability of donor NK cells to eliminate recipient DCs, thus preventing T-cell priming (47).”
BackgroundSeggewiss, R., & Einsele, H. (2010) · Blood · doi:10.1182/blood-2009-12-234096 · Cited by 297
De Maria, A., Fogli, M., Costa, P., Murdaca, G., Puppo, F., Mavilio, D., Moretta, A., & Moretta, L. (2003) · European Journal of Immunology · doi:10.1002/eji.200324141 · Cited by 299
NK Cell Compartments and Their Activation by Dendritic Cells
Ferlazzo, G., & Münz, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1333 · Cited by 299
“E-mail addresses: ferlazg@mail.rockefeller.edu and munzc@mail.rockefeller.edu 3 Abbreviations used in this paper: NCR, natural cytotoxicity receptor; ULBP, UL16 binding protein; KIR, killer inhibitory receptor; DC, dendritic cell; MCMV, murine CMV; AML, acute myeloid leukemia; GvHD, graft-vs-host disease.”
BackgroundInfluentialCD56bright NK cells exhibit potent antitumor responses following IL-15 priming
Wagner, J. A., Rosario, M., Romee, R., Berrien-Elliott, M. M., Schneider, S. E., Leong, J. W., Sullivan, R. P., Jewell, B. A., Becker-Hapak, M., Schappe, T., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90387 · Cited by 297
“Early after an HCT, CD56bright NK cells are the major lymphocyte subset to recover in the peripheral blood (73–78).”
BackgroundResultInfluentialCerboni, C., Zingoni, A., Cippitelli, M., Piccoli, M., Frati, L., & Santoni, A. (2007) · Blood · doi:10.1182/blood-2006-10-052720 · Cited by 297
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
Jena, B., Dotti, G., & Cooper, L. J. N. (2010) · Blood · doi:10.1182/blood-2010-01-043737 · Cited by 297
Natural killer cell homing and trafficking in tissues and tumors: from biology to application
Ran, G. H., Lin, Y. Q., Tian, L., Zhang, T., Yan, D. M., Yu, J. H., & Deng, Y. C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01058-z · Cited by 282
“reported that outcomes of patients with acute myeloid leukemia (AML) transplanted with hematopoietic stem cells (HSCs) correlated positively with the anti-leukemic effect of allogeneic NK cells.(23) In a pioneering study in 2005, Miller et al.”
BackgroundCastriconi, R., Dondero, A., Augugliaro, R., Cantoni, C., Carnemolla, B., Sementa, A. R., Negri, F., Conte, R., Corrias, M. V., Moretta, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405025101 · Cited by 294
Huang, X.-J., Liu, D.-H., Liu, K.-Y., Xu, L.-P., Chen, H., Han, W., Chen, Y.-H., Zhang, X.-H., & Lu, D.-P. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.11.025 · Cited by 294
“[18] were 60% for AML and 40% for ALL, respectively.”
BackgroundInfluentialNatural killer cell–directed therapies: moving from unexpected results to successful strategies
Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N., & Zitvogel, L. (2008) · Nature Immunology · doi:10.1038/ni1580 · Cited by 289
“Indeed, NK cell alloreactivity eliminated the AML cells as well as host DC”
BackgroundMiller, J. S., Cooley, S., Parham, P., Farag, S. S., Verneris, M. R., McQueen, K. L., Guethlein, L. A., Trachtenberg, E. A., Haagenson, M., Horowitz, M. M., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065383 · Cited by 288
Leong, J. W., Chase, J. M., Romee, R., Schneider, S. E., Sullivan, R. P., Cooper, M. A., & Fehniger, T. A. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.01.006 · Cited by 285
“Initial reports in the MHC-haploidentical transplantation setting indicated that NK cells may be harnessed for graft-versusleukemia effects in the absence of graft-versus-host disease [9].”
BackgroundUnrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?
Grewal, S. S., Barker, J. N., Davies, S. M., & Wagner, J. E. (2003) · Blood · doi:10.1182/blood-2002-08-2510 · Cited by 284
Kohrt, H. E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., et al. (2014) · Blood · doi:10.1182/blood-2013-08-519199 · Cited by 283
“In addition, lack of KIR-HLA class I interactions has been associated with potent NK-mediated antitumor efficacy and increased survival in acute myeloid leukemia (AML) patients upon haplo-identical stem cell transplantation from KIR mismatched donors.(8) To exploit this pathway pharmacologically, the fully human mAb a…”
BackgroundSurface NK receptors and their ligands on tumor cells
Moretta, L., Bottino, C., Pende, D., Castriconi, R., Mingari, M. C., & Moretta, A. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.03.002 · Cited by 283
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Vey, N., Bourhis, J.-H., Boissel, N., Bordessoule, D., Prebet, T., Charbonnier, A., Etienne, A., Andre, P., Romagne, F., Benson, D., et al. (2012) · Blood · doi:10.1182/blood-2012-06-437558 · Cited by 278
NK cells and ILCs in tumor immunotherapy
Sivori, S., Pende, D., Quatrini, L., Pietra, G., Della Chiesa, M., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., et al. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100870 · Cited by 270
Natural killer cells: In health and disease
Mandal, A., & Viswanathan, C. (2015) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2014.11.006 · Cited by 271
Passweg, J. R., Tichelli, A., Meyer-Monard, S., Heim, D., Stern, M., Kühne, T., Favre, G., & Gratwohl, A. (2004) · Leukemia · doi:10.1038/sj.leu.2403524 · Cited by 270
Developmental and Functional Control of Natural Killer Cells by Cytokines
Wu, Y., Tian, Z., & Wei, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00930 · Cited by 269
“Previous studies have observed that NK cells can exert graft-versus-leukemia reactions without causing graft-versus-host disease (GVHD) in allogeneic hematopoietic transplantation (259).”
BackgroundThe Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Souza-Fonseca-Guimaraes, F., Cursons, J., & Huntington, N. D. (2019) · Trends in Immunology · doi:10.1016/j.it.2018.12.003 · Cited by 279
Engineered cellular immunotherapies in cancer and beyond
Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G., & June, C. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01765-8 · Cited by 269
Woll, P. S., Grzywacz, B., Tian, X., Marcus, R. K., Knorr, D. A., Verneris, M. R., & Kaufman, D. S. (2009) · Blood · doi:10.1182/blood-2008-06-165225 · Cited by 268
Pende, D., Castriconi, R., Romagnani, P., Spaggiari, G. M., Marcenaro, S., Dondero, A., Lazzeri, E., Lasagni, L., Martini, S., Rivera, P., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2696 · Cited by 268
Sakamoto, N., Ishikawa, T., Kokura, S., Okayama, T., Oka, K., Ideno, M., Sakai, F., Kato, A., Tanabe, M., Enoki, T., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0632-8 · Cited by 270
“Lack of KIR-HLA class I interactions has been associated with potent NK-mediated antitumor efficacy in acute myeloid leukemia patients upon haplo-identical stem cell transplantation [36] or NK cells infusion [6, 37] from KIR mismatched donors.”
BackgroundAdoptive Immunotherapy for Cancer or Viruses
Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M., Zhao, Y., & June, C. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120136 · Cited by 264
Chen, S., Zhu, H., & Jounaidi, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02005-w · Cited by 234
“472 473 – 475 However, the effectiveness of allogeneic donor NK stimulated ex-vivo is reduced by competition for cytokines 79,476 and approaches relying only on CAR technology, as CAR-NK cells suffer from tumor cell escape by HLA aberrant expression and epitope loss.”
BackgroundMesenchymal stromal cells and the innate immune response
Le Blanc, K., & Davies, L. C. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.05.004 · Cited by 262
Limits of HLA mismatching in unrelated hematopoietic cell transplantation
Petersdorf, E. W., Anasetti, C., Martin, P. J., Gooley, T., Radich, J., Malkki, M., Woolfrey, A., Smith, A., Mickelson, E., & Hansen, J. A. (2004) · Blood · doi:10.1182/blood-2004-04-1674 · Cited by 263
“Median recipient age, y (range) 37 (2-55) 34 (1-62)”
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Mehta, R. S., & Rezvani, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00283 · Cited by 259
“Rather, experimental evidence obtained in mice have reported reduced risk of GVHD with NK cells via multiple mechanisms, including depletion of host antigen-presenting cells and activated alloreactive T cells (46, 72, 175, 176).”
BackgroundHarnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Maskalenko, N. A., Zhigarev, D., & Campbell, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00413-7 · Cited by 256
Licensing of natural killer cells by self‐major histocompatibility complex class I
Yokoyama, W. M., & Kim, S. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00458.x · Cited by 259
Immunomodulatory Effects of Dietary Polyphenols
Shakoor, H., Feehan, J., Apostolopoulos, V., Platat, C., Al Dhaheri, A. S., Ali, H. I., Ismail, L. C., Bosevski, M., & Stojanovska, L. (2021) · Nutrients · doi:10.3390/nu13030728 · Cited by 251
“NK cells have a strong cytolytic function and a considerable role in immune regulation [43].”
BackgroundShilling, H. G., McQueen, K. L., Cheng, N. W., Shizuru, J. A., Negrin, R. S., & Parham, P. (2003) · Blood · doi:10.1182/blood-2002-08-2568 · Cited by 257
Immunobiology of acute graft-versus-host disease
Reddy, P., & Ferrara, J. L. M. (2003) · Blood Reviews · doi:10.1016/s0268-960x(03)00009-2 · Cited by 242
Reconstitution of the immune system after hematopoietic stem cell transplantation in humans
Storek, J., Geddes, M., Khan, F., Huard, B., Helg, C., Chalandon, Y., Passweg, J., & Roosnek, E. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0132-5 · Cited by 250
“host APC that prime alloreactive T cells causing GVHD (63).”
Tallerico, R., Todaro, M., Di Franco, S., Maccalli, C., Garofalo, C., Sottile, R., Palmieri, C., Tirinato, L., Pangigadde, P. N., La Rocca, R., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201542 · Cited by 251
“NK cells preparation was done as described elsewhere (37).”
BackgroundDAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Töpfer, K., Cartellieri, M., Michen, S., Wiedemuth, R., Müller, N., Lindemann, D., Bachmann, M., Füssel, M., Schackert, G., & Temme, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1400330 · Cited by 249
“HLA-B andHLA-Cmismatch predicting for a KIR-mismatch in the graft-versus-host (GvH) direction was calculated according to the published “missing ligand” model (11) and using KIR-ligand calculator software (www.”
BackgroundMethodNguyen, S., Dhedin, N., Vernant, J.-P., Kuentz, M., Jijakli, A. A., Rouas-Freiss, N., Carosella, E. D., Boudifa, A., Debré, P., & Vieillard, V. (2005) · Blood · doi:10.1182/blood-2004-10-4113 · Cited by 250
“NK cells were analyzed after staining with an appropriate antibody cocktail: anti-CD45 (HI30), anti-CD3 (UCHT1; BD Biosciences Pharmingen), anti-CD56 (NKH1; Beckman-Coulter, Marseille, France), anti-KIR2DL1/ CD158a (HP-3E4), anti-KIR2DL2/CD158b (CH-L), anti-KIR3DL1/ CD158e/NKB1 (DX9), anti-2B4 (2-69), anti-CD16 (3G8;…”
Functional subsets of mouse natural killer cells
Hayakawa, Y., Huntington, N. D., Nutt, S. L., & Smyth, M. J. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00454.x · Cited by 244
Ciurea, S. O., Mulanovich, V., Saliba, R. M., Bayraktar, U. D., Jiang, Y., Bassett, R., Wang, S. A., Konopleva, M., Fernandez-Vina, M., Montes, N., et al. (2012) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2012.07.003 · Cited by 250
“Donors were selected with consideration of a negative serum sample for donor-specific anti-HLA Abs before transplantation [14], being ABO matched rather than mismatched, male rather than female, and, if feasible, by the presence of killer immunoglobulinlike receptor (KIR)-ligand-mismatch in the graftversus-host direct…”
Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications
Carlsten, M., & Childs, R. W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00266 · Cited by 243
“These studies showed that haplo-identical donor NK cells could prevent relapse in acute myeloid leukemia (AML) following hematopoietic stem cell transplantation (HSCT) and that adoptively infused mature donor NK cells could induce remission in AML patients (6, 10).”
BackgroundInnate and adaptive immunity: specificities and signaling hierarchies revisited
Vivier, E., & Malissen, B. (2005) · Nature Immunology · doi:10.1038/ni1153 · Cited by 246
“Although the development of innate immunity-based innovative therapies awaits further development, the manipulation and adoptive transfer of innate immune effectors may be feasible because it is potentially safe and predictable.”
Targeting the extrinsic apoptosis signaling pathway for cancer therapy
Sayers, T. J. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1008-4 · Cited by 241
“NK cells are lytic to tumor cells but their adoptive transfer may not pose many of the problems, such as graft-versus-host disease, that are associated with the transfer of allogeneic T cells [ 50 ] NK cells not only utilize the perforin-dependent lytic pathway but can also be a rich source of TRAIL and FasL.”
BackgroundWillemze, R., Rodrigues, C. A., Labopin, M., Sanz, G., Michel, G., Socié, G., Rio, B., Sirvent, A., Renaud, M., Madero, L., et al. (2009) · Leukemia · doi:10.1038/leu.2008.365 · Cited by 245
Benson, D. M., Hofmeister, C. C., Padmanabhan, S., Suvannasankha, A., Jagannath, S., Abonour, R., Bakan, C., Andre, P., Efebera, Y., Tiollier, J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438028 · Cited by 244
Uterine Natural Killer Cells: Functional Distinctions and Influence on Pregnancy in Humans and Mice
Gaynor, L. M., & Colucci, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00467 · Cited by 250
“NK cells from HLA haplotype-mismatched donors enhance graft tolerance in patients with acute myeloid leukemia and induce disease remission with protection against relapse (149).”
BackgroundTargeting natural killer cells in solid tumors
Habif, G., Crinier, A., André, P., Vivier, E., & Narni-Mancinelli, E. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0224-2 · Cited by 241
In Vivo Survival and Homeostatic Proliferation of Natural Killer Cells
Prlic, M., Blazar, B. R., Farrar, M. A., & Jameson, S. C. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021847 · Cited by 243
Farag, S. S., Bacigalupo, A., Eapen, M., Hurley, C., Dupont, B., Caligiuri, M. A., Boudreau, C., Nelson, G., Oudshoorn, M., van Rood, J., et al. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2006.05.007 · Cited by 243
Self-citationGleason, M. K., Verneris, M. R., Todhunter, D. A., Zhang, B., McCullar, V., Zhou, S. X., Panoskaltsis-Mortari, A., Weiner, L. M., Vallera, D. A., & Miller, J. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0692 · Cited by 238
“HCT and are key mediators of graft versus leukemia reactions againstminimal residual disease providing protection against relapse (44).”
BackgroundMolecular Pathways: Interleukin-15 Signaling in Health and in Cancer
Mishra, A., Sullivan, L., & Caligiuri, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3603 · Cited by 244
Airoldi, I., Bertaina, A., Prigione, I., Zorzoli, A., Pagliara, D., Cocco, C., Meazza, R., Loiacono, F., Lucarelli, B., Bernardo, M. E., et al. (2015) · Blood · doi:10.1182/blood-2014-09-599423 · Cited by 238
NK cells regulating T cell responses: mechanisms and outcome
Crouse, J., Xu, H. C., Lang, P. A., & Oxenius, A. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.11.001 · Cited by 242
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
Childs, R. W., & Carlsten, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4506 · Cited by 236
Hilpert, J., Grosse-Hovest, L., Grünebach, F., Buechele, C., Nuebling, T., Raum, T., Steinle, A., & Salih, H. R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200796 · Cited by 238
“Further evidence for the ability of NK cells to combat leukemia in humans has been provided by clinical data from allogenic stem cell transplantation (5, 6).”
BackgroundPyo, C.-W., Guethlein, L. A., Vu, Q., Wang, R., Abi-Rached, L., Norman, P. J., Marsh, S. G. E., Miller, J. S., Parham, P., & Geraghty, D. E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015115 · Cited by 236
“There is increasing evidence that taking account of the immunogenetics of KIR can improve the outcome of allogeneic hematopoietic cell transplantation as therapy for acute myelogenous leukemia [16,55,56,57].”
BackgroundSpanholtz, J., Preijers, F., Tordoir, M., Trilsbeek, C., Paardekooper, J., de Witte, T., Schaap, N., & Dolstra, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020740 · Cited by 238
“Furthermore, we have evaluated CD34+ cells-derived NK cell generation in static cell culture bags and an automated bioreactor, with the aim of optimizing fully closed, large-scale production of highly active and functional NK cells for the use in a phase I dose-finding trial in elderly AML patients not eligible for al…”
BackgroundInfluentialShah, N. N., Baird, K., Delbrook, C. P., Fleisher, T. A., Kohler, M. E., Rampertaap, S., Lemberg, K., Hurley, C. K., Kleiner, D. E., Merchant, M. S., et al. (2015) · Blood · doi:10.1182/blood-2014-07-592881 · Cited by 238
“The dose of T cells administered,#23 10(4)/kg, was unlikely to be the sole cause for the rate of high-grade aGVHD observed in these HLA-matched recipients.(8) Furthermore, the T-cell content of the aNK-DLI, following CD3 depletion, was required to be less than,0.”
BackgroundCurrent perspectives of natural killer cell education by MHC class I molecules
Höglund, P., & Brodin, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2835 · Cited by 237
“This process is known as missing-self recognition and has been observed in allogeneic stem cell transplantation, in which it can contribute to a potent graft-versus-leukaemia effect and improve patient surviva”
BackgroundThe Pathophysiology of Acute Graft-versus-Host Disease
Ferrara, J. L. M., Cooke, K. R., & Teshima, T. (2003) · International Journal of Hematology · doi:10.1007/bf02983793 · Cited by 235
“The general elimination of host APCs by activated natural killer (NK) cells can prevent GVHD [23].”
BackgroundReddy, P., Maeda, Y., Liu, C., Krijanovski, O. I., Korngold, R., & Ferrara, J. L. M. (2005) · Nature Medicine · doi:10.1038/nm1309 · Cited by 236
Carlsten, M., Björkström, N. K., Norell, H., Bryceson, Y., van Hall, T., Baumann, B. C., Hanson, M., Schedvins, K., Kiessling, R., Ljunggren, H.-G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2264 · Cited by 234
“In part, this was explained by clearance of dendritic cells known to initiate T-cell–mediated GVHD disease (8, 37), but the lack of GVHD also implies a capacity of NK cells to discriminate tumor cells from normal tissues.”
BackgroundHuman Embryonic Stem Cell-Derived NK Cells Acquire Functional Receptors and Cytolytic Activity
Woll, P. S., Martin, C. H., Miller, J. S., & Kaufman, D. S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5095 · Cited by 233
“NK cells provide important cell-mediated antitumor activity, as clearly demonstrated in recent clinical trials (56, 57).”
BackgroundCytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors
Cho, D., Shook, D. R., Shimasaki, N., Chang, Y.-H., Fujisaki, H., & Campana, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0735 · Cited by 234
“Natural killer (NK) cells can kill allogeneic hematopoietic cells, and have been administered either in the setting of hematopoietic stem cell transplantation or after non-myeloablative immunosuppressive therapy to enhance the effect of chemotherapy in patients with acute leukemia, yielding encouraging results [13-17].”
BackgroundStringaris, K., Sekine, T., Khoder, A., Alsuliman, A., Razzaghi, B., Sargeant, R., Pavlu, J., Brisley, G., de Lavallade, H., Sarvaria, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.087536 · Cited by 231
Shouval, R., Fein, J. A., Labopin, M., Kröger, N., Duarte, R. F., Bader, P., Chabannon, C., Kuball, J., Basak, G. W., Dufour, C., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30158-9 · Cited by 231
Allogeneic Stem Cell Transplantation: A Historical and Scientific Overview
Singh, A. K., & McGuirk, J. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1311 · Cited by 234
“The success of transplant for hematologic malignancies derives both from the ability to treat patients with intensive chemoradiotherapy and from potent graft-versus-leukemia (GVL) effects mediated by donor immunity.”
BackgroundInfluentialAllogeneic natural killer cell therapy
Berrien-Elliott, M. M., Jacobs, M. T., & Fehniger, T. A. (2023) · Blood · doi:10.1182/blood.2022016200 · Cited by 224
Metadata
- Authors
- Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., & Velardi, A.
- Affiliations
- University of Perugia (IT)
- Yale University (US)
- Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy.
- Ospedale Policlinico San Martino (IT)
- ORCID
- Venue
- Science
- Published
- 2002-03-15
- Volume
- 295
- Issue
- 5562
- Pages
- 2097-2100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2147068163
- Cited by
- 3,380
- References
- 21
- Citations by year
- 2026: 46 · 2025: 92 · 2024: 112 · 2023: 134 · 2022: 157 · 2021: 156 · 2020: 139 · 2019: 155 · 2018: 140 · 2017: 157 · 2016: 152 · 2015: 171 · 2014: 134 · 2013: 162 · 2012: 150
- FWCI
- 63.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL03979)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- natural killer cells, NK cell alloreactivity, allogeneic hematopoietic stem cell transplantation, mismatched transplantation, graft-versus-host disease, graft rejection, leukemia relapse, T cell depletion, conditioning intensity, leukemia
- MeSH terms
- Acute Disease, Animals, Antigen-Presenting Cells, Graft Survival, Graft vs Host Disease, H-2 Antigens, Haplotypes, Histocompatibility Testing, Humans, Killer Cells, Natural, Leukemia, Myeloid, Mice, Inbred Strains, Receptors, Immunologic, Recurrence, T-Lymphocytes, Bone Marrow Transplantation, Mice, SCID, Mice, Inbred NOD, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning, Graft vs Leukemia Effect, Mice, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Receptors, KIR
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.